BPMUF OTC
Basilea Pharmaceutica AG
1W: -1.5%
1M: -1.5%
3M: +26.5%
YTD: +20.6%
1Y: +12.6%
3Y: +86.0%
5Y: +41.2%
$76.25
-1.15 (-1.49%)
Weekly Expected Move ±0.7%
$75
$76
$76
$77
$77
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$282M
+9.5% ▲
5Y CAGR: +4.2%
Total Liabilities
$154M
-12.8% ▼
5Y CAGR: -14.2%
Shareholders Equity
$128M
+58.0% ▲
Cash & Investments
$162M
+34.6% ▲
5Y CAGR: +0.1%
Total Debt
$101M
-9.6% ▼
5Y CAGR: -16.1%
Net Debt
$71M
+890.0% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $54M | $85M | $60M | $121M | $30M |
| Short-Term Investments | $95M | $0 | $52M | $0 | $133M |
| Cash & ST Investments | $149M | $85M | $60M | $121M | $162M |
| Net Receivables | $25M | $57M | $28M | $57M | $63M |
| Inventory | $23M | $24M | $26M | $32M | $22M |
| Other Current Assets | $85M | $10M | $38M | $12M | $5M |
| Total Current Assets | $241M | $175M | $152M | $221M | $252M |
| Property, Plant & Equip. | $3M | $22M | $21M | $19M | $18M |
| Goodwill & Intangibles | $632K | $578K | $548K | $374K | $371K |
| Long-Term Investments | -$93M | $23M | $0 | $0 | $0 |
| Other Non-Current Assets | $279K | $23M | $44K | $146K | $51K |
| Total Non-Current Assets | $6M | $45M | $21M | $37M | $30M |
| Total Assets | $247M | $221M | $173M | $258M | $282M |
| — Liabilities — | |||||
| Accounts Payable | $11M | $191K | $6M | $11M | $15M |
| Short-Term Debt | $124M | $37M | $15M | $0 | $2M |
| Deferred Revenue | $34M | $27M | $0 | $0 | $2M |
| Other Current Liabilities | -$22M | -$11M | $11M | $32M | $20M |
| Total Current Liabilities | $174M | $75M | $48M | $46M | $49M |
| Long-Term Debt | $95M | $131M | $95M | $96M | $87M |
| Other Non-Current Liab. | $25M | $33M | $15M | $10M | -$3M |
| Total Non-Current Liabilities | $131M | $191M | $136M | $131M | $105M |
| Total Liabilities | $306M | $266M | $183M | $177M | $154M |
| — Equity — | |||||
| Common Stock | $13M | $13M | $13M | $13M | $13M |
| Retained Earnings | -$1.0B | -$1.0B | -$1.0B | -$923M | -$883M |
| Accumulated OCI | -$22M | -$4M | -$10M | -$5M | -$4M |
| Total Stockholders Equity | -$59M | -$45M | -$10M | $81M | $128M |
| Total Liabilities & Equity | $247M | $221M | $173M | $258M | $282M |
| — Key Metrics — | |||||
| Total Debt | $219M | $187M | $129M | $112M | $101M |
| Net Debt | $165M | $102M | $69M | -$9M | $71M |
| Total Investments | $2M | $23M | $52M | $0 | $133M |